Clinical Trial Update: 90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating consolidation with 90Y-ibritumomab tiuxetan after six cycles of R-CHOP in patients with bulky diffuse large B-cell lymphoma has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• 90Y-ibritumomab tiuxetan (ibritumomab tiuxetan)

Snippet

Sponsor: Chonnam National University Hospital | Conditions: Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: COMPLETED